TL;DR: CMS modified NCD 129 governing Medicare coverage for the treatment of actinic keratosis, effective March 7, 2026. Here's what billing teams need to know.

The Centers for Medicare & Medicaid Services updated NCD 129 — the National Coverage Determination governing Medicare coverage for actinic keratosis (AK) destruction. The coverage policy itself is favorable: Medicare covers AK destruction without restrictions based on lesion or patient characteristics, for services performed on and after November 26, 2001. This modification formalizes and clarifies that standing policy under NCD 129 in the CMS Medicare system. No specific CPT or HCPCS codes are enumerated in this policy document, which means your billing team will need to cross-reference current claims processing instructions and applicable local coverage determinations to confirm code-level guidance.


Quick-Reference Table

Field Detail
Payer CMS (Centers for Medicare & Medicaid Services)
Policy Treatment of Actinic Keratosis
Policy Code NCD 129
Change Type Modified
Effective Date 2026-03-07
Impact Level Medium
Specialties Affected Dermatology, Primary Care, Physician Assistant Services
Key Action Confirm your actinic keratosis billing aligns with NCD 129's unrestricted coverage standard and pull current MAC-level LCD guidance for code-specific requirements

CMS Actinic Keratosis Coverage Criteria and Medical Necessity Requirements 2026

NCD 129 sets a broad standard. Medicare covers the destruction of actinic keratoses without restrictions based on lesion characteristics or patient characteristics. That's the CMS actinic keratosis coverage policy in plain terms.

The effective date for this coverage standard is November 26, 2001 — this modification on March 7, 2026 updates the policy record without narrowing that coverage. The practical effect is that you don't need to document specific lesion size, number, location, or histologic grade to establish medical necessity for AK destruction under this NCD.

That said, "no restrictions" at the NCD level doesn't mean your Medicare Administrative Contractor can't impose tighter standards through a local coverage determination. Many MACs have active LCDs that add documentation requirements on top of NCD 129. If your MAC has an LCD for AK destruction, those local rules govern your claims. Check your MAC's LCD portal now — before the effective date of March 7, 2026 — to confirm what's required in your region.

Medical necessity documentation still matters even when coverage is unrestricted. Your records should reflect that the provider evaluated the lesion, confirmed the AK diagnosis, and selected an appropriate treatment. The policy notes clinicians should base treatment selection on the patient's medical history, the lesion's characteristics, and the patient's preference. Document all three. An audit or claim denial is much harder to fight when that clinical rationale isn't in the chart.

Prior authorization is not mentioned as a requirement under NCD 129 for standard AK destruction. However, if your practice performs less common AK treatments — dermabrasion, chemical peels, laser therapy, or photodynamic therapy — check with your MAC and any applicable commercial payers. Those modalities carry more scrutiny and may require prior authorization depending on the payer and clinical context.


Coverage Indications at a Glance

Indication Status Relevant Codes Notes
Destruction of actinic keratoses (any lesion, any patient) Covered Not specified in NCD 129 — see MAC LCD and claims processing instructions No restrictions on lesion or patient characteristics; effective November 26, 2001
Cryosurgery with liquid nitrogen for AKs Covered Not specified in NCD 129 Commonly performed; document clinical rationale
Topical drug therapy for AKs Covered Not specified in NCD 129 Confirm reimbursement under applicable drug benefit category
+ 7 more indications

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

This policy is now in effect (since 2026-03-12). Verify your claims match the updated criteria above.

CMS Actinic Keratosis Billing Guidelines and Action Items 2026

NCD 129 is good news for your reimbursement picture — broad, unrestricted coverage is a billing team's friend. But "unrestricted" doesn't mean "undocumented." Here's what to do before and after the effective date of March 7, 2026.

#Action Item
1

Pull your MAC's LCD for AK destruction right now. NCD 129 sets the floor — no restrictions — but your Medicare Administrative Contractor can layer local requirements on top. Go to your MAC's website, search for any active LCD covering destruction of benign or premalignant skin lesions, and compare those documentation requirements to your current workflow. If there's a gap, close it before March 7, 2026.

2

Confirm the correct CPT codes with your MAC's claims processing instructions. NCD 129 does not list specific CPT or HCPCS codes. That's the most operationally important thing to understand about this policy. Pull the cross-referenced claims processing instructions from CMS directly, and verify with your MAC which destruction codes apply to AK services. Common destruction codes exist in the CPT surgery section, but confirming the exact codes your MAC expects is non-negotiable for clean claim submission.

3

Update your documentation templates to reflect NCD 129's three-factor treatment rationale. The policy is explicit: treatment selection should be based on patient medical history, lesion characteristics, and patient preference. Build those three elements into your encounter note template. That documentation supports medical necessity and protects you in a post-payment audit.

+ 3 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

Sample Version Diff Line-by-line changes
Previous VersionCurrent Version
Coverage is considered experimental and investigational for all indicationsCoverage is considered medically necessary when specific criteria are met
Prior authorization is not requiredPrior authorization is required for initial treatment
Documentation must include clinical historyDocumentation must include clinical history
+ 1 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

CPT, HCPCS, and ICD-10 Codes for Actinic Keratosis Treatment Under NCD 129

NCD 129 does not enumerate specific CPT, HCPCS, or ICD-10 codes. This is a known limitation of this policy document, and it has real operational consequences for actinic keratosis billing.

What This Means for Your Billing Team

CMS directs billers to the cross-referenced claims processing instructions for code-level guidance. You need to retrieve those instructions directly from CMS or your MAC to confirm which codes are recognized under this NCD.

Do not assume a code is covered under NCD 129 simply because it describes an AK treatment. The absence of an explicit code list means your MAC's LCD — and your MAC's claims processing instructions — carry significant weight in determining which codes pass through cleanly.

Where to Find the Applicable Codes

If your billing team isn't sure which CPT codes your MAC recognizes for AK destruction, call your MAC's provider relations line before March 7, 2026. This is not a step to skip — submitting claims with unsupported codes under an NCD that doesn't list codes is a fast path to claim denial and potential takebacks.


Get the Full Picture

Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.

🔍 Search by any code 🔔 Real-time alerts 📊 Line-by-line diffs ⏰ Deadline tracking
Get Full Access → $99/mo · 14-day money-back guarantee